CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.
Fenofibrate: TriCor, Lipanthyl, Lipantil
|M03-661||Hyperlipidemia||CSR.ORG||A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetim More»|
|M02-514||Pharmacokinetics||CSR.ORG||Effect of Multiple Doses of Fenofibrate on the Multiple-Dose Pharmacokinetics of Pravastatin in Healthy Subjects Gustavson LE More»|
No results found